Katsumata N

No ORCID on file · 1 paper in corpus · active 2002
2002
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.
Japanese journal of cancer research : Gann ·doi:10.1111/j.1349-7006.2002.tb01231.x

Ovarian clear cell adenocarcinoma (CCA) is generally chemo-resistant. Recently the poor prognosis and resistance to chemotherapeutic agents of HER2/neu over-expressing tumors have become clear. Thus, we investigated the expression level of …